Immuneering Corporation

Contributing Author

Recent Articles by Immuneering Corporation

Jun-17	Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients IMRX GlobeNewswire
Jun-16	Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 IMRX GlobeNewswire
May-29	Immuneering to Present at the Jefferies Global Healthcare Conference IMRX GlobeNewswire
May-05	Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates IMRX GlobeNewswire